title: Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs.
abstract: In this paper we report on three different hydrophilic copolymers based on alpha,beta-polyaspartylhydrazide (PAHy) bearing butyric groups in the side chain (C 4) (PAHy-C 4) or a combination of butyric groups and positive charged residues ((carboxypropyl)trimethylammonium chloride, CPTACl) (PAHy-C 4-CPTA) that were synthesized and used for the preparation of new supramolecular vesicular aggregates (SVAs) containing gemcitabine as an antitumor drug. Gemcitabine-loaded SVAs containing synthesized PAHy derivatives were characterized from the physicochemical and technological point of view and the in vitro toxicity and anticancer activity on two different human cancer cell lines, i.e., CaCo-2 (human colon carcinoma) and ARO (human anaplastic thyroid carcinoma) cells, were also evaluated. Moreover, considering that carrier-cell interaction is an important factor to achieve an improvement of anticancer drug activity, confocal laser scanning microscopy and flow cytometric experiments were carried out on the two different cancer cell lines.
authors.affiliation: Department of Pharmacobiological Sciences, Faculty of Pharmacy, University Magna Graecia of Catanzaro, Campus Universitario, Building of Biosciences, Viale Europa, I-88100 Germaneto (CZ), Italy.
authors.forename: D
authors.initials: D
authors.lastname: Paolino
authors.forename: D
authors.initials: D
authors.lastname: Cosco
authors.forename: M
authors.initials: M
authors.lastname: Licciardi
authors.forename: G
authors.initials: G
authors.lastname: Giammona
authors.forename: M
authors.initials: M
authors.lastname: Fresta
authors.forename: G
authors.initials: G
authors.lastname: Cavallaro
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D002478:Cells, Cultured; D002850:Chromatography, Gel / Q000379:methods; D002851:Chromatography, High Pressure Liquid; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005434:Flow Cytometry; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D015394:Molecular Structure; D010455:Peptides / Q000737:chemistry*; D011108:Polymers / Q000138:chemical synthesis / Q000737:chemistry*; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004337:Drug Carriers; D010455:Peptides; D011108:Polymers; C442699:poly(aspartylhydrazide); D003841:Deoxycytidine; D000093542:Gemcitabine